ShelleyHwangMDMPH
General Surgery • Durham, NCBreast, Surgical Oncology (Other than Breast)
Professor and Vice Chair Research
Dr. Hwang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2301 Erwin Rd
Durham, NC 27710Phone+1 919-684-6849
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1992 - 1996
Kaiser Permanente Southern California (Los Angeles)Internship, Surgery, 1991 - 1992
David Geffen School of Medicine at UCLAClass of 1991
Certifications & Licensure
CA State Medical License 1993 - Present
NC State Medical License 2011 - 2025
NY State Medical License 1993 - 1998- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Start of enrollment: 2002 Feb 19
- Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Start of enrollment: 2017 May 31
- Examining Bioactivity of PVSRIPO in Invasive Breast Cancer Start of enrollment: 2019 Jun 30
Roles: Contact
Publications & Presentations
PubMed
- 96 citationsLobular breast cancer series: imagingKaren S. Johnson, Deba P. Sarma, E. Shelley Hwang
Breast Cancer Research. 2015-07-11 - 154 citationsTrends in Treatment Patterns and Outcomes for Ductal Carcinoma in SituMathias Worni, Igor Akushevich, Rachel A. Greenup, Deba P. Sarma, Marc D. Ryser
Journal of the National Cancer Institute. 2015-12-01 - 4 citationsContemporary management of ductal carcinoma in situ and lobular carcinoma in situ.Samilia Obeng-Gyasi, Cecilia Ong, E. Shelley Hwang
Chinese Clinical Oncology. 2016-05-11
Journal Articles
- Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening TrialsShelley Hwang, MD, American Journal of Epidemiology
- Association of Low Nodal Positivity Rate Among Patients with ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Che...Henry M Kuerer, Judy C Boughey, Alison U Barron, E Shelley Hwang, JAMA
- The Association of Extent of Axillary Surgery and Survival in Women with N2–3 Invasive Breast CancerJennifer K Plichta, Oluwadamilola M Fayanju, Rachel C Blitzblau, Rachel A Greenup, Laura H Rosenberger, E Shelley Hwang, Cecilia T Ong, Annals of Surgical Oncology
- Join now to see all
Press Mentions
Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy SurgeryOctober 29th, 2024- New USPSTF Draft Suggests Mammography Start at 40, Not 50May 9th, 2023
- New Gene Classifier Identifies Risk of Breast Pre-Cancer Progression, Duke and Stanford Researchers ReportNovember 21st, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
